Exchange: NASDAQ·Updated 07:54 PM EDT

CORT News

News
all
press releases
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
Healthcare stocks like Abbott Laboratories offer low-beta exposure as rate hike fears and inflation keep markets volatile.
Zacks
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
Healthcare stocks like Abbott Laboratories offer low-beta exposure as rate hike fears and inflation keep markets volatile.
Zacks
More News
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
Zacks
Is Aspen Pharmacare (APNHY) Stock Outpacing Its Medical Peers This Year?
Here is how Aspen Pharmacare (APNHY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.
Zacks
Corcept Announces Planned Leadership Transition
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of...
Business Wire
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.
Zacks
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant)
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European...
Business Wire
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years
Corcept Therapeutics (NASDAQ:CORT) has outperformed the market over the past 10 years by 20.4% on an annualized basis producing an average annual return of 33.86%. Currently, Corcept Therapeutics has a marketread more...
Benzinga
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
Zacks
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks

Advertisement|Remove ads.